Efficacy and Safety of Doctor Decha’s Cannabis Oil on Sleep Quality, Quality of Life and Glycemic Control in Patients with Type 2 Diabetes: A Prospective Controlled Clinical Study
Article Sidebar
Main Article Content
Abstract
Cannabis has been increasingly investigated as an adjunctive therapy for chronic conditions due to its potential effects on sleep, well-being and metabolic regulation, but clinical evidence for patients with type 2 diabetes remains limited. This prospective controlled clinical study evaluated the efficacy and safety of Doctor Decha’s cannabis oil on sleep quality, quality of life and glycemic control in patients with type 2 diabetes at Kamphaeng Phet Hospital. Fifty eight patients aged 30–70 years diagnosed with type 2 diabetes mellitus were allocated into two groups: the intervention group received 0.15 mL of Doctor Decha’s cannabis oil orally once daily at bedtime for three months, while the control group received standard care according to hospital protocols. Sleep quality (Pittsburgh Sleep Quality Index, PSQI), quality of life (WHOQOL-BREF) and glycated hemoglobin (HbA1c) were assessed at the baseline and after treatment. Safety was monitored through liver and kidney function tests and adverse event reporting. Results showed significant improvements in the intervention group. Mean PSQI score decreased from 10.14 ± 2.22 to 4.45 ± 0.91 (within-group p < 0.001), while the WHOQOL-BREF score improved from 0.85 ± 0.08 to 0.96 ± 0.06 (p < 0.001) including physical, psychological and social domains (between-group p < 0.05). HbA1c declined from 9.21 ± 1.61% to 8.53 ± 1.72% (p < 0.05). Between-group differences were not significant and no serious adverse events or abnormal liver or kidney functions were detected. Doctor Decha’s cannabis oil was safe and effectively improved sleep and quality of life, with modest glycemic benefits. However, a larger sample size with a longer trial period would further confirm the results.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
1. Association AD. Standards of care in diabetes-2023 abridged for primary care providers. Clin Diabetes. 2023;41(1):4-31. Doi: 10.2337/cd23-as01.
2. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep. 2024;7(3):e2004. Doi: 10.1002/hsr2.2004.
3. Aekplakorn W, Tantayotai V, Numsangkul S, Tatsato N, Luckanajantachote P, Himathongkam T. Evaluation of a community-based diabetes prevention program in Thailand: a cluster randomized controlled trial. J Prim Care Community Health. 2019;10:2150132719847374. Doi: 10.1177/2150132719847374.
4. Parker ED, Lin J, Mahoney T, Ume N, Yang G, Gabbay RA, ElSayed NA, Bannuru RR. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2023;47(1):26-43. Doi: 10.2337/dci23-0085.
5. Bromberg T, Gasquet NC, Ricker CN, Wu C. Healthcare costs and medical utilization patterns associated with painful and severe painful diabetic peripheral neuropathy. Endocr J. 2024;86(3):1014-1024. Doi: 10.1007/s12020-024-03954-6.
6. Xu H, Chen Q. The bidirectional influence between type 2 diabetes mellitus and the state of depression and anxiety. J Affect Disord. 2025;386:119467. https://doi.org/10.1016/j.jad.2025.119467.
7. Fanelli G, Raschi E, Hafez G, Matura S, Schiweck C, Poluzzi E, Lunghi C. The interface of depression and diabetes: treatment considerations. Transl Psychiatry. 2025;15(1):22. Doi: 10.1038/s41398-025-03234-5.
8. Reda D. Narrative review of metabolic syndrome and its relationships with non-alcoholic fatty liver disease, gonadal dysfunction and obstructive sleep apnea. Diabetol Metab Syndr. 2025;17(1):353. Doi: 10.1186/s13098-025-01903-5.
9. Gentile S, Monda VM, Guarino G, Satta E, Chiarello M, Caccavale G, Mattera E, Marfella R, Strollo F. Obstructive sleep apnea and type 2 diabetes: an update. J Clin Med. 2025;14(15). Doi: 10.3390/jcm14155574.
10. Rubin RR, Peyrot M. Psychological issues and treatments for people with diabetes. J Clin Psychol. 2001;57(4):457-478. Doi: 10.1002/jclp.1041.
11. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669. Doi: 10.2337/dci18-0033.
12. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-442. Doi: 10.2337/dc14-2441.
13. Przeor M. Some Common Medicinal Plants with Antidiabetic Activity, Known and Available in Europe (A Mini-Review). Pharmaceuticals (Basel). 2022;15(1). 10.3390/ph15010065.
14. Kopustinskiene DM, Masteikova R, Lazauskas R, Bernatoniene J. Cannabis sativa L. bioactive compounds and their protective role in oxidative stress and inflammation. Antioxidants (Basel). 2022;11(4):660. Doi: 10.3390/antiox11040660.
15. Yongram C, Meeboonya R, Chokchaisiri S, Wonganan O, Sansila P, Kaewudom P, Kakatum N, Kanjanakaroon Y, Kamoltham T, Roongpisuthipong A. A qualitative ethnopharmacological analysis of cannabis-based formulations for insomnia in Thai traditional medicine recipes. Trop J Nat Prod Res. 2025;9(6):2673-2683. https://doi.org/10.26538/tjnpr/v9i6.43.
16. Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017;19(4):1-12. Doi: 10.1007/s11920-017-0775-9.
17. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013;17(4):475-490. Doi: 10.1016/j.cmet.2013.03.001.
18. Prasanth MI, Sivamaruthi BS, Sharika R, Leonard IJ, Gayathri PN, Tencomnao T, Chuchawankul S. Updated medicinal uses of marijuana in Thailand (Cannabis species in Thai traditional medicine). Medicinal properties and ,olecular mechanisms of Thai traditional herbs. 1st Edition: CRC Press; 2025. p. 182-204.
19. Nakkliang K. Standardization and DNA barcoding of cannabis in Thailand and pharmacological properties of cannabis-based Thai traditional medicine formula extract (Kealomkeasan). Chulalongkorn University: Chulalongkorn University, Thailand; 2022.
20. Stienrut P, Pongpirul K, Phutrakool P, Savigamin C, Sermsaksasithorn P, Chanhom O, Jeamjumrus P, Pongchaichanon P, Nootim P, Soisamrong M, Chuthaputti A, Wanaratna K, Thaneerat T. Medical cannabis prescription practices and quality of life in Thai patients: a nationwide prospective observational cohort study. Med Cannabis Cannabinoids. 2024;7(1):125-137. Doi: 10.1159/000540153.
21. Carpi M. The Pittsburgh Sleep Quality Index: a brief review. Occup Med (Lond). 2025;75(1):14-15. Doi: 10.1093/occmed/kqae121.
22. Almarabheh A, Salah AB, Alghamdi M, Al Saleh A, Elbarbary A, Al Qashar A, Alserdieh F, Alahmed F, Alhaddar H, Alsada L, Yosri M, Omran M, Khudhair M, Salih M, Fuad N, Chlif S. Validity and reliability of the WHOQOL-BREF in the measurement of the quality of life of Sickle disease patients in Bahrain. Front Psychol. 2023;14 1219576. Doi: 10.3389/fpsyg.2023.1219576.
23. Bunreungthong K, Boonyarat C, Welbat JU, Nillert N, Pannangrong W. Total phenolic and flavonoid contents, antioxidant activity of Antidesma velutinosum extract and effect of the extract on spatial memory in rats. Srinagarind Med J. 2023;38(4):409-415.
24. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016;37(3):278-316. Doi: 10.1210/er.2015-1137.
25. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013;93(1):137-188. Doi: 10.1152/physrev.00045.2011.
26. Reutrakul S, Van Cauter E. Sleep influences on obesity, insulin resistance, and risk of type 2 diabetes. Metabolism. 2018;84:56-66. Doi: 10.1016/j.metabol.2018.02.010.
27. McCallion A. Assessing and addressing psychosocial and physiological risk factors of type 2 diabetes, by combining a novel lifestyle modification programme with low intensity CBT. Coleraine campus: Ulster University; 2022.
28. Tasali E, Van Cauter E, Ehrmann DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):36-42. Doi: 10.1210/jc.2005-1084.
29. D'Angelo M, Steardo L, Jr. Cannabinoids and sleep: exploring biological mechanisms and therapeutic potentials. Int J Mol Sci. 2024;25(7):3603. Doi: 10.3390/ijms25073603.
30. Swenson K. Beyond the hype: a comprehensive exploration of CBD's biological impacts and mechanisms of action. J Cannabis Res. 2025;7(1):24. Doi: 10.1186/s42238-025-00274-y.
31. Schouten M, Dalle S, Mantini D, Koppo K. Cannabidiol and brain function: current knowledge and future perspectives. Front Pharmacol. 2023;14:1328885. Doi: 10.3389/fphar.2023.1328885.
32. Lee S, Lee Y, Kim Y, Kim H, Rhyu H, Yoon K, Lee C-D, Lee S. Beneficial effects of cannabidiol from Cannabis. Appl Biol Chem. 2024;67(1):32. Doi: 10.1186/s13765-024-00867-w.
33. Pantanetti P, Biondini F, Mancin S, Sguanci M, Masini A, Panella M, Palomares SM, Ferrara G, Petrelli F, Cangelosi G. Sleep Quality and Glycemic Control in Type 1 Diabetes: A Retrospective Cohort Study Using Advanced Technological Devices. J diabetol 2025;6(3):21. Doi: 10.26355/eurrev_202305_32473.
34. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol (1985). 2005;99(5):2008-2019. Doi: 10.1152/japplphysiol.00660.2005.
35. Bahji A, Meyyappan AC, Hawken ER. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis. J Psychiatr Res. 2020;129:257-264. Doi: 10.1016/j.jpsychires.2020.07.030.
36. Haller J. Anxiety modulation by cannabinoids-the role of stress responses and coping. Int J Mol Sci. 2023;24(21):15777. Doi: 10.3390/ijms242115777.
37. Kitdumrongthum S, Trachootham D. An individuality of response to cannabinoids: challenges in safety and efficacy of cannabis products. Molecules. 2023;28(6):2791. Doi: 10.3390/molecules28062791.
38. Schlag AK, Hindocha C, Zafar R, Nutt DJ, Curran HV. Cannabis based medicines and cannabis dependence: a critical review of issues and evidence. J Psychopharmacol. 2021;35(7):773-785. Doi: 10.1177/0269881120986393.
39. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. J Am Med Assoc. 2015;313(24):2474-2483. Doi: 10.1001/jama.2015.6199.
40. Gonzalez-Garcia M, Ferrer MJ, Borras X, Munoz-Moreno JA, Miranda C, Puig J, Perez-Alvarez N, Soler J, Feliu-Soler A, Clotet B. Effectiveness of mindfulness-based cognitive therapy on the quality of life, emotional status, and CD4 cell count of patients aging with HIV infection. AIDS Behav. 2014;18(4):676-685. Doi: 10.1007/s10461-013-0612-z.
41. Keefe FJ, Abernethy AP, C. Campbell L. Psychological approaches to understanding and treating disease-related pain. Annu Rev Psychol 2005;56(1):601-630. Doi: 10.1146/annurev.psych.56.091103.070302.
42. Schram MT, Baan CA, Pouwer F. Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium. Curr Diabetes Rev. 2009;5(2):112-119. Doi: 10.2174/157339909788166828.
43. Stampanoni Bassi M, Gilio L, Maffei P, Dolcetti E, Bruno A, Buttari F, Centonze D, Iezzi E. Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic use against anxiety and depression. Front Mol Neurosci. 2018;11:424. Doi: 10.3389/fnmol.2018.00424.
44. Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8(6):807. Doi: 10.3390/jcm8060807.
45. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S. Cannabinoids for medical use: a systematic review and meta-analysis. J Am Med Assoc. 2015;313(24):2456-2473. Doi: 10.1001/jama.2015.6358.
46. O'Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173(12):1899-1910. Doi: 10.1111/bph.13497.
47. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27(1):73-100. Doi: 10.1210/er.2005-0009.
48. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18(1):27-37. Doi: 10.1016/j.tem.2006.11.006.
49. Aschner P, Karuranga S, James S, Simmons D, Basit A, Shaw JE, Wild SH, Ogurtsova K, Saeedi P. The International Diabetes Federation's guide for diabetes epidemiological studies. Diabetes Res Clin Pract. 2021;172:108630. Doi: 10.1016/j.diabres.2020.108630.
50. Poowanna R, Pulbutr P, Kijjoa A, Nualkaew S. Purgative Effect, Acute Toxicity, and Quantification of Phorbol-12-Myristate-13-Acetate and Crotonic Acid in Croton tiglium L. Seeds Before and After Treatment by Thai Traditional Detoxification Process. Int J Mol Sci. 2025;26(16):7714. https://doi.org/10.3390/ijms26167714.
51. Gowda S, Desai PB, Kulkarni SS, Hull VV, Math AA, Vernekar SN. Markers of renal function tests. N Am J Med Sci. 2010;2(4):170-173.
52. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. Doi: 10.1111/j.1476-5381.2011.01238.x.